Outcome

This study found that Hyperbaric Oxygen Therapy (HBOT) significantly reduced oxidative stress and inflammation in long COVID-19 patients including professional athletes. HBOT decreased reactive oxygen species lipid peroxidation DNA damage and inflammation biomarkers. These effects were notably pronounced in athletes.

Introduction

Long COVID-19 has left many individuals including professional athletes grappling with persistent symptoms and systemic inflammation that significantly impact their daily lives. In this compelling study researchers explore the potential benefits of Hyperbaric Oxygen Therapy (HBOT) in alleviating these ongoing issues. By providing 100% oxygen at 2.4 ATA in a hyperbaric chamber across 15 to 50 sessions the study revealed notable reductions in reactive oxygen species (ROS) lipid peroxidation DNA damage and nitric oxide (NO) metabolites. These anti-inflammatory effects were especially pronounced in athletes. With these promising preliminary outcomes HBOT stands out as a promising non-invasive therapy to counteract the debilitating symptoms of long COVID-19. The research underscores the therapy’s potential in enhancing the quality of life for long COVID sufferers by considerably reducing inflammation and oxidative stress markers.

Results

The study observed significant reductions in multiple biomarkers associated with oxidative stress and inflammation following Hyperbaric Oxygen Therapy (HBOT) in long COVID-19 patients including professional athletes. Participants underwent HBOT at 2.4 atmospheres absolute (ATA) over sessions ranging from 15 to 50.

Key findings include substantial decreases in reactive oxygen species (ROS) lipid peroxidation DNA damage and nitric oxide (NO) metabolites. Inflammation biomarkers also showed marked reduction post-treatment. Notably these therapeutic effects were more pronounced in athletes compared to other participants.

These results present HBOT as an effective non-invasive treatment to counteract persistent symptoms of long COVID-19 particularly emphasizing its potential to significantly improve the conditions of professional athletes. The reduction in oxidative stress and inflammation biomarkers points towards HBOT’s capacity to alleviate systemic inflammation and improve overall patient outcomes in long COVID-19 cases.

Overall the study highlights HBOT’s promising role in mitigating long-term inflammatory symptoms in long COVID-19 patients suggesting a significant improvement in quality of life through the reduction of oxidative stress markers.

Conclusion

In conclusion this study highlights the promising potential of hyperbaric oxygen therapy (HBOT) as an effective intervention for long COVID-19 demonstrating significant reductions in oxidative stress and inflammation markers. By providing 100% oxygen at 2.4 ATA across multiple sessions HBOT notably decreased reactive oxygen species lipid peroxidation DNA damage and inflammation biomarkers. This effect was particularly pronounced in professional athletes indicating that HBOT can play a pivotal role in alleviating persistent symptoms related to long COVID-19 in both the general population and physically active individuals. These findings underscore the value of HBOT as a non-invasive therapeutic option that could significantly improve the quality of life for patients battling long-term COVID-19 symptoms. Future research should focus on larger-scale studies and explore the potential applications of HBOT for other inflammation-related conditions to further validate and expand upon these preliminary outcomes.